Abstract
The clinical study on cephapirin (CEP) which was administered to the patients with pulmonary infection was done. CEP was given intravenously with 500 ml of D5/W in 2 hours.
1. In the cases with 5 g administration of CEP, the highest concentration of the drug in blood was seen at the end of intravenous infusion, and its T1/2 was 0.35 hour on average.
2. The drug concentration in sputa of the patients with bronchiectasis was 1.6 mcg/ml at highest when 3 g of CEP were given. The ratio of the level to that of the blood at the highest concentration was 0.01.
3. Sixteen patients with infection in the lower respiratory tract were treated with 3-10g daily of CEP (bronchopneumonia 6, middle lobe syndrome 1, lung abscess 2, bronchiectasis 4, chronic bronchitis 1, bacterial pneumonia complicated with lung cancer 2). CEP was markedly beneficial in 4 cases, beneficial in 3 cases, slightly beneficial in 3 cases and not beneficial in 6 cases.
4. Regarding the adverse reactions, increasing of serum transaminase level was seen, in 3 cases with 4 g administration per day (SGOT 89 u and SGPT 85 u at highest). Otherwise, the side effect was not remarkable. The increased level of SGOT and SGPT got down to normal by discontinuing the administration.
